Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors by Janes, Peter W. et al.
JCB: Article
The Rockefeller University Press    $30.00
J. Cell Biol. Vol. 195 No. 6  1033–1045
www.jcb.org/cgi/doi/10.1083/jcb.201104037 JCB 1033
Correspondence to Martin Lackmann: Martin.Lackmann@monash.edu
A. Mensinga’s present address is Dept. of Molecular Cancer Research, University 
Medical Center Utrecht, 3584 CG Utrecht, Netherlands.
C. Jørgensen’s present address is the Section of Cell and Molecular Biology, 
Institute of Cancer Research, London SW3 6JB, England, UK.
Abbreviations used in this paper: ANOVA, analysis of variance; AP, acceptor 
peptide; CRD, cysteine-rich domain; diHcRed, divalent Heteractis crispa red; 
FLIM, fluorescence lifetime imaging microscopy; FRET, Förster resonance energy 
transfer; IP, immunoprecipitate; LBD, ligand-binding domain; PY, phosphotyro-
sine; SA, streptavidin; WB, Western blot; Wt, wild type.
Introduction
Eph receptor tyrosine kinases (Ephs) and their cell-bound li-
gands (ephrins) direct cell navigation and topographic map-
ping of tissues during developmental patterning by controlling 
cell–cell adhesion and segregation (Klein, 2004; Lackmann 
and Boyd, 2008). Their important cell guidance functions 
are  increasingly  recognized  in  a  wide  variety  of  cancers, 
in  which  Ephs and ephrins function during tumor invasion, 
neoangiogenesis,  and  metastasis  (Janes  et  al.,  2008;  Pasquale, 
2010). For several Ephs, tumor suppressor roles in prostate, 
colon,  and  breast  tumors  have  been  previously  described 
(Huusko et al., 2004; Batlle et al., 2005; Noren et al., 2006).   
EphB  receptor-mediated  cell  segregation  of  colon  cancer 
cells and surrounding epithelial cells contains tumor growth 
by preventing invasion into ephrin-B–expressing tissue layers 
(Clevers and Batlle, 2006; Cortina et al., 2007), and EphB2 
mutation or epigenetic silencing is a prerequisite for tumor 
expansion and correlates with poorer patient outcomes. In 
addition to EphB2, gene array analyses for diagnostic somatic 
mutations identified several other Eph receptors, in particular 
EphA3 and EphA7, among the most frequently mutated genes 
in colorectal (Sjöblom et al., 2006) and lung (Ding et al., 2008) 
cancer. Here, the identified mutations often target protein re-
gions, including the kinase domain, likely affecting Eph signal-
ing and biological activity (Pasquale, 2010).
Eph receptors are structurally grouped into EphA recep-
tors,  preferentially  binding  glycophosphatidylinositol-linked 
A-type ephrins, and EphBs, binding transmembrane B-type 
E
ph receptors interact with ephrin ligands on ad-
jacent  cells  to  facilitate  tissue  patterning  during 
normal and oncogenic development, in which un-
scheduled expression and somatic mutations contribute to 
tumor progression. EphA and B subtypes preferentially   
bind A- and B-type ephrins, respectively, resulting in 
receptor complexes that propagate via homotypic Eph–
Eph interactions. We now show that EphA and B recep-
tors cocluster, such that specific ligation of one receptor 
promotes recruitment and cross-activation of the other. 
Remarkably, coexpression of a kinase-inactive mutant 
EphA3 with wild-type EphB2 can cause either cross- 
activation or cross-inhibition, depending on relative ex-
pression. Our findings indicate that cellular responses to 
ephrin contact are determined by the EphA/EphB recep-
tor profile on a given cell rather than the individual Eph 
subclass. Importantly, they imply that in tumor cells coex-
pressing different Ephs, functional mutations in one subtype 
may cause phenotypes that are a result of altered signaling 
from heterotypic rather from homotypic Eph clusters.
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have important implications in a tumor setting, where a range of 
Eph receptors are frequently coexpressed in the same tumor and 
where frequent somatic mutations affecting functional domains 
of certain Ephs may have more complex consequences than 
previously appreciated (Pasquale, 2010).
Results
EphA and EphB receptors associate and 
cross-phosphorylate
We demonstrated previously that, in addition to EphA re-
ceptors, preclustered ephrin-A5 binds and activates EphB2 
(Himanen et al., 2004), providing circumstantial evidence for 
the notion of cooperative signaling from EphA3 and EphB2 
receptors. We investigated this concept by transfecting HEK293 
cells with combinations of GFP-tagged EphB2 and divalent 
Heteractis  crispa  red  (diHcRed)–tagged  EphA3  receptors 
(Janes et al., 2005), discernable by their different apparent mo-
lecular masses on Western blots (WBs; Fig. 1 A, bottom blot). 
The transfected cells were exposed to preclustered ephrin-
A5-Fc,  binding  both  receptors  with  comparable  affinities 
(Himanen et al., 2004), or to IIIA4, an activating mAb with ex-
quisite specificity for EphA3 (Vearing et al., 2005). As expected, 
anti-EphB2 WB analysis of protein G pull-downs of ephrin-
A5–associated  receptors  from  cell  lysates  confirmed  EphB2 
binding, irrespective of the presence of EphA3 (Fig. 1 A, top 
blot).  Interestingly,  the  IIIA4  mAb  also  immunoprecipitated 
EphB2 but only from cells coexpressing EphA3, suggesting 
that this pull-down occurred via interaction between EphB2 and 
EphA3. Accordingly, WB analysis with antiphosphotyrosine 
(-PY) antibodies showed that IIIA4 induced phosphorylation 
not only of diHcRed-EphA3 but also of GFP-EphB2, discern-
able by its apparent lower molecular mass on WBs (Fig. 1 A, 
middle blot).
Although use of IIIA4 to oligomerize EphA3 guaranteed 
that recruitment and activation of EphB2 observed in these   
experiments is initiated by ligation of EphA3, a corresponding 
-EphB2 antibody, which would allow testing if EphB2 liga-
tion also triggers coclustering and activation of coexpressed 
EphA3, is not available. We achieved selective oligomerization 
of EphB2 by engineering EphB2 containing an N-terminal bio-
tin acceptor peptide (AP) tag (AP-EphB2), serving as a unique 
biotinylation site for the Escherichia coli biotin ligase (BirA; 
Howarth et al., 2005). Exposure of cells expressing selectively 
biotinylated Ephs to tetravalent streptavidin (SA) will tether 
these into complexes (Howarth and Ting, 2008) and effectively 
induces activation (Nievergall et al., 2010) and internalization 
(Janes et al., 2009). In the current experiments, we used SA-
coated magnetic Dynabeads to cluster and activate biotinylated 
AP-EphB2 and to allow selective recovery of AP–Eph receptor 
complexes after cell lysis. WB analysis with -PY–EphA3 
antibodies showed increasing phosphorylation peaking 20 min 
after the addition of beads (Fig. 1 B). Despite some apparent 
cross-reactivity of the antibodies for PY-EphB2 (Fig. 1 B, 
rightmost lane), a markedly increased PY-Eph signal in cells 
coexpressing both receptors indeed suggests phosphoryla-
tion of EphA3 and EphB2. Furthermore, immunoblotting with 
ephrins (Gale et al., 1996). Within these subtypes, ephrin–Eph 
interactions are largely promiscuous, but there is limited cross-
reactivity between subtypes. Known exemptions include EphA4 
ligating A- and B-type ephrins and ephrin-A5 binding all EphA 
and some EphB receptors (Himanen et al., 2004). Unlike other 
receptor tyrosine kinases, Ephs require oligomerization by cell 
surface–tethered or preclustered soluble ephrins for transphos-
phorylation, downstream signaling, and biological responses 
(Davis et al., 1994; Stein et al., 1998).
In addition to ephrin-induced oligomerization, homotypic 
interaction between Eph receptors independent of ephrin liga-
tion is essential for the assembly and lateral propagation of sig-
naling clusters (Wimmer-Kleikamp et al., 2004). The recently 
elucidated  molecular  architecture  of  the  ephrin-bound  and 
nonbound EphA2 extracellular domain (Himanen et al., 2010; 
Seiradake et al., 2010) confirmed structure/function analyses 
indicating the Eph–Eph-binding interfaces within the ephrin-
binding domain and the adjacent cysteine-rich domain (CRD; 
Lackmann et al., 1998; Wimmer-Kleikamp et al., 2004). Fur-
thermore, recent evidence further suggests that, in addition to 
Eph–ephrin and Eph–Eph interactions, actomyosin contractile 
forces modulating the actin cytoskeleton may participate in Eph 
clustering (Salaita et al., 2010).
During  developmental  patterning,  various  Eph  family 
members have overlapping expression profiles (Xu et al., 2000; 
Lackmann and Boyd, 2008), and the final position of migrating 
cells or axons is determined by the sum of the cell surface Eph 
receptors, which are competing for available ephrin targets in 
this expression domain (Reber et al., 2004). Considering the 
promiscuity of Eph–ephrin interactions, this emphasizes the 
relevance of Eph receptor coclustering for signaling outcomes, 
as demonstrated for EphB1 and EphB6 (Freywald et al., 2002) 
and for EphA3 and EphA4 (Marquardt et al., 2005). In these 
cases, formation of heterologous Eph clusters was rationalized 
by promiscuous ephrins cross-linking both Eph receptors. How-
ever, the observation that Ephs are effectively recruited into 
signaling clusters independent of ephrin tethering could suggest 
that coclustering and composite signaling might also occur with 
EphA and EphB receptors if expressed on the same cell surface. 
This would imply signaling outcomes determined by clusters 
that comprise members of both Eph subclasses rather than Ephs 
that directly interact with compatible ephrins.
Indeed, we demonstrate here for the first time that EphA 
and -B receptors, which are expressed on the same cell, assem-
ble into common signaling clusters. We provide evidence for 
functionally relevant coclusters of EphB2 and EphA2 or EphA3 
on a range of tumor cells, in which constitutive basal associa-
tion between heterotypic Ephs is increased by agonist ligation. 
Selective clustering of one of the Ephs triggers cross-activation 
of the heterologous receptors, and their combined signal deter-
mines the downstream response to a given agonist, even to the 
extent that overexpression of a kinase-inactive EphA inhibits 
EphB signaling in a dominant-negative manner. Our findings 
may help to explain some of the disparate cellular responses to 
Eph/ephrin signaling that have been reported in various biological 
and  cell  biological  systems  (Holmberg  and  Frisén,  2002; 
Pasquale, 2005; Lackmann and Boyd, 2008) and are likely to 1035 Eph receptor heterooligomerization • Janes et al.
Likewise,  quantitative  RT-PCR  of  high-grade  glioma  pa-
tient  samples  showed  frequent  coexpression  of  EphA  and 
EphB  family  members,  indicating  that  their  coexpression  is 
prevalent in the primary cells and not a consequence of tis-
sue culture (Fig. S1). Coimmunoprecipitation from U251 cells 
showed that IIIA4 treatment increased EphA3 activation and 
constitutive association with EphB2 (Fig. 1 C, left). Further-
more, -PY WBs of EphB2 and EphA3 IPs from ephrin-B1-Fc   
and IIIA4-treated U251 cells (Fig. 1 C, right) indicate that 
both agonists trigger activation of EphA3 and of EphB2; more 
prominent phosphorylation in EphB2 IPs from ephrin-B1-Fc–
stimulated cells and in EphA3 IPs from IIIA4-stimulated cells 
suggests preferential activation of either Eph by its specific 
agonist and coactivation of the other associated Eph receptor. In 
agreement, dissociation of EphB2 from -EphA3 IPs prepared 
from ephrin-B1–stimulated U251 cells accordingly reduces the 
-PY signal to intermediated levels above basal phosphoryla-
tion (Fig. S2 A), implying that both Ephs are coactivated during 
ephrin-B1 stimulation. Coclustering between EphAs and EphBs 
is also apparent in prostate cancer cells. LNCaP cells coexpress 
EphA3  and  EphB2,  and  both  receptors  were  coprecipitated 
from cell lysates with the -EphA3 mAb (Fig. S2 B). In PC3 
cells lacking detectable EphA3, but coexpressing EphA2 and 
EphB2, -EphB2 IP antibodies revealed association between 
these two Ephs (Fig. S2 C). Together, these data support the 
notion that receptor coclustering likely occurs among various 
EphA and -B family members.
EphA and -B receptors associate  
in intact cells
To verify that EphA3 and EphB2 coclustering is not a con-
sequence of cell lysis but occurs in intact cells, we analyzed 
Eph–Eph interactions by confocal microscopy in AP-EphA3/
HEK293  cells  that  had  been  transfected  with  EphB2-GFP. 
Staining of intact cells with Alexa Fluor 594–tagged IIIA4 
revealed noticeably colocalized GFP and Alexa Fluor 594 fluor-
escence on the cell surface, including on filopodia-like cell 
extensions (arrows and inset in top row of Fig. 2 A). To induce 
discernable localized clustering of AP-EphA3, we added SA-
coated beads to these cells, prompting not only recruitment   
of biotinylated EphA3-AP but also of EphB2-GFP to the cell 
surface–attached beads (Fig. 2 A, bottom row).
Although clustering with SA-coated beads is efficient for 
activation of the biotinylated AP-EphA3, it does not allow endo-
cytosis of activated receptors to proceed (Nievergall et al., 2010). 
To assess whether the two different Eph receptors are endo-
cytosed within the same vesicles, we exposed GFP-EphB2 and 
diHcRed-EphA3–expressing cells to preclustered Alexa Fluor 
647 IIIA4. Confocal microscopy revealed diHcRed-EphA3, 
Alexa Fluor 647 IIIA4, and GFP-EphB2 fluorescence colocal-
ized in surface-proximal vesicles, likely representing early 
endosomes (Fig. 2 B, top row; Nievergall et al., 2010). Impor-
tantly, we observed colocalized endocytosis also in cells express-
ing kinase-inactive, PY signaling–defective EphB2[3YF] with   
phenylalanine substitutions at three regulatory tyrosine phos-
phorylation sites (Figs. 2 B [bottom row] and S3 A; Binns et al., 
2000; Wybenga-Groot et al., 2001). In agreement, comparison 
-EphA3  antibodies  confirmed  that  increasing  association 
between EphA3 and AP-EphB2 coincides with Eph activation. 
Some EphA3 is discernible also in immunoprecipitates (IPs) 
from cells transfected with AP-EphB2 alone (Fig. 1 B, right-
most lane), likely reflecting the moderate endogenous EphA3 
expression found in HEK293T cells (Dottori et al., 1999).
Next,  we  determined  whether  coassociation  between 
EphA and EphB receptors is possible in cells endogenously co-
expressing both receptor classes. Screening of a range of tumor cell   
lines for EphA/B receptor coexpression revealed high levels of   
EphA3 and EphB2 in glioblastoma cell lines, including U251 cells.   
Figure 1.  EphA3 and EphB2 coIP from cells and are coactivated by receptor- 
specific stimulation. (A) HEK293T cells transfected with diHcRed-EphA3 
or  GFP-EphB2  were  stimulated  for  15  min  with  ephrin-A5-Fc  (A5-Fc),   
-EphA3 mAb (IIIA4), or not stimulated (control [cont]). Ephrin or IIIA4-
bound receptors were analyzed by a WB with the indicated antibodies. 
To control loading, lysates were blotted with -EphA3 and -EphB2 anti-
bodies (bottom). Prot G p/down, protein G pull-down. (B) HEK293T cells 
transfected with EphA3 and/or with biotin ligase–treated AP-EphB2 were 
incubated with SA-coated Dynabeads for various times or with ephrin-B1-
Fc/protein A Dynabeads as a control. Beads were recovered from cell 
lysates, and associated proteins were analyzed by a WB with -EphA3 
or  –PY-EphA3  antibodies.  To  control  loading,  total  lysates  were  also 
blotted with -EphA3 and -EphB2 antibodies (bottom panels). (C) U251 
glioma cells were treated with cross-linked IIIA4 and ephrin-B1-Fc to spe-
cifically activate EphA3 and EphB2, respectively, or left untreated (cont).   
(left) EphA3 IPs were immunoblotted for EphA3, PY, or associated EphB2. 
(right) Parallel EphB2 and EphA3 IPs were immunoblotted with -EphA3, 
-EphB2, and -PY antibodies, as indicated.JCB • VOLUME 195 • NUMBER 6 • 2011   1036
close  proximity  between  EphB2  and  a  signaling-inactive 
EphA3[3YF] mutant (Fig. 2 C, bottom row), corroborating that 
intracellular PY signaling is not required for the association 
between the two receptors. In control experiments, acceptor 
photobleaching resulted in complete abrogation of attenuated 
donor fluorescence lifetimes (Fig. S3 C), confirming FRET 
between closely adjacent fluorophore-tagged receptors as a 
basis for the observed short YFP lifetimes.
Next, we investigated the protein domains involved in 
heterotypic Eph clustering. Previously, we demonstrated homo-
typic oligomerization of EphA3 via extracellular domain inter-
actions (Wimmer-Kleikamp et al., 2004) and, by structural 
analysis of full EphA2 exodomain, identified the Eph–Eph 
interaction interfaces within the ligand-binding domain (LBD) 
and the adjacent CRD (Himanen et al., 2010). Coprecipitation 
of EphB2 with Wt or truncated EphA2 indicated that deletion of 
the LBD resulted in almost complete loss of the EphB2 associa-
tion, whereas CRD deletion had a lesser effect (Fig. 3 A).   
of IPs from cells expressing either wild-type (Wt) EphA3 and 
EphB2  or  their  tyrosine/phenylalanine  substitution  mutants 
confirmed coassociation between these Ephs, independent of 
their PY signal capacity (Fig. S3 B).
Next, we studied the suggested interaction between the 
EphA and EphB receptors at increased spatial resolution using 
fluorescence lifetime imaging microscopy (FLIM), an approach 
that monitors a 1–10-nm proximity (Wouters et al., 2001; Jares-
Erijman and Jovin, 2003) of donor and acceptor fluorophores 
(in our case, EphB2-YFP and EphA3-diHcRed, respectively). 
Depending on their distance, Förster resonance energy transfer 
(FRET) from the donor (EphB2-YFP) to the acceptor (EphA3-
diHcRed) results in decreased donor fluorescence lifetimes, 
indicated in the figures by blue color coding. In agreement 
with  our  other findings, YFP fluorescence lifetime maps of 
YFP-EphB2  and  diHcRed-EphA3–cotransfected  COS7  cells 
reveal substantial IIIA4-enhanced interaction between the two 
receptors (Fig. 2 C). Importantly, FLIM analysis also reveals 
Figure 2.  Association of EphA3 and EphB2 in intact cells. 
(A)  Colocalization  of  AP-EphA3  and  GFP-EphB2  in  cells. 
HEK293 cells expressing biotinylated AP-EphA3 were trans-
fected with GFP-EphB2. After 24 h, cells were stained with 
Alexa Fluor 647 -EphA3 (IIIA4; red) before (top) or after 
(bottom) the addition of Alexa Fluor 594 SA–coated beads 
for  20  min,  fixed,  and  imaged  by  confocal  microscopy.   
(B) Cointernalization of EphA3 and EphB2. HEK293 cells 
were  transfected  with  Wt  diHcRed-EphA3  and  Wt  GFP-
EphB2 or inactive mutant GFP-EphB2[3YF]. After 24 h, cells 
were stimulated for 20 min with cross-linked Alexa Fluor 647 
IIIA4 before fixation and confocal microscopy. (A and B)   
Arrows  indicate  prominent  colocalization.  Insets  show   
details in boxed areas at higher magnification. (C) Fluores-
cence lifetime microscopy shows close association of YFP-
EphB2 and Wt or diHcRed-EphA3[3YF] in live cells. COS7 
cells were transfected with YFP-EphB2 and Wt or 3YF mutant 
diHcRed-EphA3, and FRET between YFP and diHcRed was 
analyzed by FLIM before and after 40 min of stimulation 
with clustered IIIA4. YFP fluorescence lifetime maps are il-
lustrated together with confocal micrographs of YFP-EphB2 
and diHcRed-EphA3–transfected COS7 cells. All scale bars 
are in micrometers.1037 Eph receptor heterooligomerization • Janes et al.
EphB2 activation (Fig. 5 A, A3KM hi). In a parallel experiment,   
we confirmed that similarly high expression levels of Wt EphA3 
notably enhanced ephrin-B1– as well as IIIA4-stimulated EphB2 
activation, whereas, by comparison, COS7 cells expressing mu-
tant EphA3[K653M] revealed strongly reduced EphB2 phos-
phorylation (Fig. 5 B).
Next, we investigated whether this dominant-negative   
inhibition of EphB2 activation by mutant EphA3 also trans-
lated into attenuation of Eph-induced cell morphology changes; 
indeed,  whereas  parental  COS7  cells  and  a  Wt  EphA3– 
expressing COS7 line responded to ephrin-B1 with strong cell 
retraction,  those  with  abundant  EphA3[K653M]  did  not   
respond (Fig. 5, C and D; and Videos 3–6), with moderate 
retraction  evident  only  in  cells  with  low  EphA3[K653M]   
expression (Video 6).
In  agreement,  EphA3  mutants  lacking  the  CRD  and  LBD 
show increasingly impaired association with EphB2 (Fig. 3 B). In-
terestingly, truncation of the whole EphA3 cytoplasmic domain 
also slightly affected heteroclustering with EphB2.
Eph heterooligomerization modulates 
signaling and cell retraction
To unambiguously assess whether Eph signaling outcomes are 
indeed determined by heterologous clusters of A and B family 
members, we tested whether muted signaling by the kinase-
inactive EphA receptor can be rescued by coclustering with the 
kinase-active EphB receptor. We used COS7 cells with endog-
enous EphB2 expression, which respond to ephrin-B stimulation, 
with marked cell retraction and cytoskeletal collapse (Koolpe 
et al., 2005), for transfection either with Wt EphA3 or with a 
kinase-inactive ATP-binding site mutant, EphA3[K653M]. In 
cells expressing Wt EphA3, selective EphA3 activation with 
preclustered Alexa Fluor 594 IIIA4 resulted in rapid cell round-
ing and retraction (Fig. 4 A, middle row), whereas a neighbor-
ing cell with low or undetectable EphA3 remained relatively 
unaffected (Fig. 4 A and Video 1). In agreement, parental COS7 
cells lacking EphA3 expression did not respond (Fig. 4 B), con-
firming that IIIA4 directly binds and clusters only EphA3 but 
not endogenous EphB2. Remarkably, cells expressing the mu-
tant, kinase-inactive EphA3[K653M], responded in a similar 
manner (Fig. 4, A [bottom row] and B and Video 2), suggesting 
cooperative signaling via endogenous EphB2.
Next, we tested in HEK293 cells with low endogenous Eph 
expression whether coexpression of mutant EphA3[K653M] 
with  EphB2  rescues  phosphorylation  of  the  kinase-inactive 
EphA3 receptor. Use of GFP-EphB2 allowed to unambiguously 
distinguish between the two Ephs of similar endogenous size in 
WBs. Cells transfected with varying amounts of each receptor 
were  stimulated  with  IIIA4,  and  bound  receptor  complexes 
were recovered and probed with -PY antibodies. As expected, 
kinase-dead  EphA3[K653M]  was  not  phosphorylated  when 
expressed on its own, whereas coexpression with high levels of 
EphB2 caused its robust phosphorylation (second lane of the 
top blot in Fig. 4 C). Interestingly, increasing the relative level 
of EphA3[K653M] compared with Wt EphB2 altered the level 
of phosphorylation of both receptors, suggesting possible inhi-
bition of EphB2 activation by high levels of kinase-inactive 
EphA3 relative to EphB2. Thus, we analyzed cells coexpressing 
overall constant levels of GFP-EphB2 and EphA3, the latter   
at decreasing ratios of Wt and EphA3[K653M]. As expected, 
maximal phosphorylation of EphA3 and EphB2 was increas-
ingly attenuated at increasing ratios of EphA3[K653M] over Wt 
EphA3, so that only background phosphorylation remained in 
the absence of Wt EphA3 (Fig. 4 D, EphA3 Wt/KM, 0:3).
To  further  investigate  this  dominant-negative  cross-
inhibition of a coclustered family member by signaling-defective 
EphA3[K653M],  we  compared  ephrin-B1–induced  EphB2 
activation in COS7 cells and in COS7 cells stably expressing 
either Wt EphA3 or mutant EphA3[K653M] (Fig. 5, A and B). 
Wt EphA3 increased ephrin-B1–induced EphB2 phosphoryla-
tion, consistent with cooperative signaling, whereas over-
expression of kinase-dead EphA3[K653M] effectively ablated   
Figure  3.  Eph  extracellular  domains  mediate  heterooligomerization.  
(A) HEK293T cells were transfected with Wt EphB2 alone (control [cont]) 
or with GFP-tagged EphA2 constructs, either full length (Wt) or lacking 
the LBD or CRD. EphB2 IPs were analyzed for associated GFP-EphA2 
by an -GFP WB and an -EphB2 blot to confirm equal loading. Relative 
expression of GFP-EphA2 constructs was assessed by a WB of total cell 
lysates (bottom). (B) HEK293 cells were transfected with Wt EphB2 and 
AP-EphA3, full length (Wt) or lacking the CRD, LBD, or intracellular 
domain (ICD). EphB2 IPs were analyzed for associated AP-EphA3 by an 
-AP WB. Relative expression of constructs was tested by an -AP IP/WB 
and anti-EphB2 blots of total cell lysates. The graph shows relative EphA3 
coIP/EphA3 expression from densitometry. A representative dataset from 
two independent experiments is shown.JCB • VOLUME 195 • NUMBER 6 • 2011   1038
ephrin expression (Nievergall et al., 2010). In contrast, cells 
expressing  cytoplasmic-truncated  EphB2ICD  (Jørgensen 
et al., 2009) lose this ability and intermingle with ephrin-
expressing cells. Thus, we tested whether the cell-sorting ca-
pacity of EphB2ICD cells could be rescued by coexpression 
of Wt EphA3, which has negligible affinity for ephrin-B1   
(Lackmann et al., 1997). Indeed, in cocultures with ephrin-B1   
cells, HEK293 cells stably expressing EphB2ICD together with 
EphA3  were  clearly  segregated  into  individual  colonies 
(Fig. 6 A, fourth row). Furthermore, the ability for segre-
gation of Wt EphB2 cells coexpressing EphA3 was nota-
bly increased relative to parental EphB2/HEK293 cells. By 
comparison, control HEK293 clones stably expressing only   
EphA3 segregated marginally from ephrin-B1 cells, confirm-
ing that direct ephrin-B1–EphA3 interactions contribute lit-
tle to the segregation ability of EphB2ICD/EphA3 cells but 
Modulation of cell segregation by  
Eph heterooligomers
To test cell biological consequences of Eph heteroclustering 
in a more physiological setting, we used a recently developed 
cell  coculture  system,  modeling  Eph/ephrin-mediated  tissue 
boundary formation (Mellitzer et al., 1999) by monitoring seg-
regation between Eph- and ephrin-expressing cells in 2D tissue 
culture (Poliakov et al., 2008; Jørgensen et al., 2009). Coculture 
of HEK293T cells expressing either ephrin-B1 or EphB2, the 
latter labeled with CellTracker green (Fig. 6) for ease of rec-
ognition, results in two distinct cell populations of green and 
unlabeled cells.
As  expected,  coculture  with  ephrin-B1–expressing 
cells results in tighter EphB2 colonies with brighter fluores-
cence intensity than what is seen in cocultures with parental 
HEK293T cells (Fig. 6 A, top two rows) with low endogenous 
Figure 4.  Cross-activation of EphA3 and B2 can rescue an inactivated EphA3 receptor to induce cell retraction. (A) Wt or EphA3[KM]-expressing COS7 
cells were stimulated with Alexa Fluor 594––EphA3-mAb IIIA4 and imaged by brightfield (top row) and fluorescence (bottom rows) live-cell microscopy. 
Brackets in the fluorescent images depict cell diameters at the start of the experiment. The numbers above the images refer to time in minutes. All scale bars   
are in micrometers. (B) Quantification of parental COS7 or Wt- or EphA3[KM]-expressing cells retracting after IIIA4 stimulation, analyzed as in A (mean ±   
SEM; >90 cells/point from multiple fields). (C) Phosphorylation of EphA3[KM] by coexpression with EphB2. HEK293T cells, cotransfected with varying 
amounts of EphA3 (KM mutant) and GFP-EphB2, were stimulated with cross-linked IIIA4 and IIIA4-bound complexes analyzed by an -PY WB. Antirecep-
tor blots of lysates show relative expression levels, with irrelevant lanes removed. The graphs show relative EphA3/B2 (rel. A3KM/B2) expression from 
densitometry, using a representative dataset from two independent experiments. Black lines indicate that intervening lanes have been spliced out. p/down, 
pull-down. (D) Kinase-inactive EphA3 suppresses EphB2 activity. HEK293 cells transfected with constant levels of GFP-EphB2 and EphA3 (varying ratios 
of Wt to EphA3[KM], as indicated) and IIIA4-stimulated complexes were recovered on and Western blotted with -PY antibodies. Cell lysates were also 
blotted for EphB2 and EphA3 as controls.1039 Eph receptor heterooligomerization • Janes et al.
The notion from cancer genome screens of function- 
impeding  somatic  EphA3  mutations  (Ding  et  al.,  2008)   
together with our findings prompted us to assess whether 
overexpression of kinase-dead EphA3 would also affect eph-
rin-B1/EphB2–mediated cell sorting in a dominant-negative 
manner. Thus, we compared cell segregation by GFP-EphB2/
HEK293T  cells  (Jørgensen  et  al.,  2009)  transfected  with 
Wt or mutant EphA3[K653M] and isolated for EphA3 ex-
pression by FACS with Alexa Fluor 594 IIIA4. Although   
coexpression of Wt EphA3 had no significant effect on the seg-
regation capacity of GFP-EphB2, strikingly, coexpression of 
EphA3[K653M] in EphB2/GFP-expressing cells effectively   
inhibited their segregation from ephrin-B1 cells (Fig. 7, A and B), 
demonstrating that abundance of the kinase-inactive EphA 
receptor  attenuates  signaling  and  biological  responses  of 
ephrin-activated EphB receptors.
that EphA3 is recruited into the ephrin-B1/EphB2ICD clus-
ter and, upon cross-activation, relays the signal for segregation. 
Consistent with this, -PY WBs of IPs from ephrinB1-Fc– 
treated  EphB2ICD/EphA3  and  Wt  EphB2/EphA3  cells   
reveal greatly enhanced phosphorylation of EphA3 relative 
to control HEK293 cells expressing EphA3 alone (Fig. 6 C). 
Interestingly,  in  EphA3/HEK293  cells  exposed  to  ephrin-
B1/HEK293 cells instead of ephrin-B1-Fc, a small amount of 
EphA3 phosphorylation is visible, likely reflecting the low-level 
expression of endogenous ephrin-A in these cells (Nievergall 
et al., 2010) and explaining the low-level segregation that we   
observe  when  these  two  cell  lines  are  cocultured  (Fig.  6, 
A and B). In agreement, coculture of nontransfected parental 
HEK293T  and  EphA3/HEK293T  cells  resulted  in  similar 
EphA3 phosphorylation, whereas preclustered ephrin-B1-Fc 
was ineffective (Fig. S4).
Figure 5.  Overexpression of kinase-dead EphA3 
blocks EphB2 activation and cell retraction. Com-
parison of EphB2 phosphorylation in Wt EphA3 
and  EphA3[KM]  COS7  cell  lines.  (A)  Parental 
COS7 cells (COS7) and clones stably expressing 
Wt EphA3 (wtA3) or high levels of K653M-EphA3 
(A3KM hi) stimulated for 15 min with ephrin-B1-
Fc were lysed, and -PY Sepharose (4G10) IPs 
were analyzed by an -EphB2 WB. -EphA3 and   
-EphB2  blots  from  total  cell  lysate  antibodies 
show relative receptor expression levels. (B) Paren-
tal COS7 cells and clones stably overexpressing 
high levels of Wt EphA3 (wt EphA3 hi) or mod-
erate levels of EphA3[KM] were stimulated with 
ephrin-B1-Fc or IIIA4, and -EphB2 and -EphA3 
IPs were Western blotted for EphB2 phosphory-
lation  and  Eph  receptor  expression  levels,  as 
indicated.  (C)  Ephrin-B1–induced  cell  retraction 
is  blocked  by  exogenous  kinase-dead  EphA3. 
COS7 cells overexpressing Wt EphA3 (top four 
rows)  or  EphA3[KM]  (bottom  two  rows)  were 
labeled  with  (noncross-linked)  Alexa  Fluor  594 
IIIA4  to  indicate  EphA3  expression,  stimulated 
with cross-linked ephrin-B1-Fc, and analyzed by 
time-lapse fluorescence live-cell imaging. Cell re-
traction is imaged in a group of three cells that 
are part of a larger cell cluster (top two rows) and 
also in a single EphA3 Wt–expressing cell demon-
strating more pronounced cell contraction (middle 
two rows). The numbers above the images refer   
to time in minutes. All scale bars are in micro-
meters. (D) The percentage of retracting cells with   
detectable EphA3 expression was quantified from 
B and compared with levels of parental COS7 
cells (mean ± SEM; n > 3). cont, control.JCB • VOLUME 195 • NUMBER 6 • 2011   1040
phosphatase fusion proteins have been used to define the Eph/
ephrin specificity subclasses (Gale et al., 1996; Pasquale, 2004) 
through interaction with relevant Eph family members (Cheng 
et al., 1995; Gale et al., 1996; Compagni et al., 2003; Marquardt 
et al., 2005).
Recently, global phosphoproteomic analysis of interact-
ing EphB2- and ephrin-B1–expressing HEK293 cells suggested 
coincident  regulation  of  EphA  receptors  in  EphB2-activated 
cells (Jørgensen et al., 2009). We now demonstrate for the first 
time that A- and B-type Ephs, when coexpressed in the same 
cell, directly associate with each other in a common signaling 
complex. Accordingly, the recruitment of Eph receptors into a 
signaling cluster can occur independent of the ephrin specificity 
and is mediated by Eph–Eph interactions. As a consequence, 
the coexpression of Eph family members, even those that are 
Discussion
Upon contact with ephrin-expressing cells, Eph receptors elicit 
cellular signaling and biological outcomes by assembly of oligo-
meric  signaling  clusters;  compelling  experimental  evidence 
over the past decade attests that it is the sum of Ephs on a 
given cell competing for available ephrins on interacting cells,   
which determines the cellular response (Brown et al., 2000; 
Reber et al., 2004), typically adhesion or segregation between 
the interacting cells (Davy and Soriano, 2005; Pasquale, 2005; 
Egea and Klein, 2007). In recognition of the two Eph/ephrin 
specificity subclasses (Gale et al., 1996; Pasquale, 2004), it has 
been generally assumed that individual signaling clusters com-
prise Eph receptors, which are competent to interact with 
the corresponding ephrins. Indeed, ephrin-Fc or ephrin–alkaline 
Figure 6.  EphA3 rescues defective cell segregation 
of EphB2ICD cells from ephrin-B1 cells. (A) Ephrin-B1   
HEK293  cells  were  cocultured  with  CellTracker 
green–labeled HEK293 cells expressing the indicated 
combinations of Wt or truncated EphB2 (ICD) and 
EphA3. At confluency (2–3 d), cells were fixed and 
imaged  by  phase-contrast  and  fluorescence  micros-
copy. The scale bar shown is in micrometers. (B) Seg-
regation of green-labeled and nonlabeled HEK293T 
cells was determined by measuring the tightness of 
(green) HEK293 cell aggregation and quantified by 
estimating mean fluorescence intensity per total fluor-
escence  area  (>12  random  fields/condition).  To  il-
lustrate  equal  fluorescence  intensity  of  CellTracker 
green–labeled cells, insets in A illustrate comparisons 
of individual nonclustered cells (magnified from areas 
defined by dashed boxes) with those selected from 
the  coculture  of  ephrin-B1/HEK293T  and  (green) 
Wt EphB2/EphA3 cells with maximal cell segrega-
tion. Statistical relevance of observed differences be-
tween all groups was determined using the analysis 
of variance (ANOVA) test for multiple comparisons. 
Means  with  error  bars  indicating  95%  confidence 
intervals  (ANOVA)  are  shown.  (C)  EphA3  is  acti-
vated in response to ephrin-B1-Fc in Wt EphB2 and 
EphB2[ICD]-coexpressing cells but not in cells lack-
ing EphB2. HEK293T cell lines illustrated in A were 
analyzed for EphA3 phosphorylation in response to 
cross-linked ephrin-B1-Fc by analyzing -EphA3 IPs by 
an -PY WB. To test ephrin-B1 stimulation of EphA3, 
EphA3/HEK293T cells were incubated with ephrin-
B1-Fc, IIIA4 (positive control), or ephrinB1/293 cells. 
To  control  loading,  lysates  were  blotted  for  EphA3 
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transphosphorylation to occur. Thus, mutant EphA3[K653M] 
lacks kinase activity and phosphorylated tyrosines when ex-
pressed on its own. In the presence of coexpressed EphB2 and 
the EphA3 agonist IIIA4, it becomes tyrosine phosphorylated 
and effectively triggers cell contraction and cell–cell segrega-
tion, suggesting a tight functional complex between the EphA 
and EphB receptors.
Clearly, our investigation required an Eph agonist that, 
unlike ephrins, binds only one of the interacting Ephs; the 
-EphA3 mAb IIIA4, which binds and exclusively activates 
EphA3 (Vearing et al., 2005), allowed the unambiguous detec-
tion of corecruitment and cross-activation of nonligated recep-
tors. A previous mutagenesis screen mapped the IIIA4-binding 
site adjacent to the postulated low-affinity EphA3/ephrin-A5 
heterodimerization interface, which is thought to link two high-
affinity Eph/ephrin heterodimers into the heterotetrameric 
complex that promotes Eph/Eph oligomerization and effective 
Eph signaling (Smith et al., 2004). Recent crystal structures of 
EphA2–ephrin-A5 or –ephrin-A1 complexes (Himanen et al., 
2010;  Seiradake  et  al.,  2010)  confirmed  these  protein  inter-
faces, suggesting that IIIA4 mimics the role of ephrin-A5-Fc 
by tethering two EphA3 receptors via their heterotetrameriza-
tion sites to promote oligomerization (Vearing et al., 2005). 
In addition to these prominent interfaces facilitating Eph clus-
tering, models derived from Eph crystal structures suggest a 
unable to bind the ligand on the interacting cell, can modulate 
signaling and biological responses of other Eph receptors en-
gaged in ephrin interactions.
During  embryogenesis,  several  Eph  and  ephrin  family 
members are coexpressed within interacting cell populations 
(Lemke and Reber, 2005; Lackmann and Boyd, 2008; Pasquale, 
2010) and on individual cells (Marquardt et al., 2005). Genetic 
studies indicate, for example, that during axonal path finding, 
multiple overlapping Eph expression gradients and their com-
bined signaling control axon branching and final growth cone 
position (Reber et al., 2004; McLaughlin and O’Leary, 2005; 
Flanagan, 2006). Not surprisingly, tumors and tumor cell lines 
also frequently coexpress several Eph and ephrin family mem-
bers (Hafner et al., 2004, 2006; Herath et al., 2006; Alonso-C   
et al., 2009), and mounting evidence suggests that Eph signaling 
and the resulting cell biological responses triggered by inter-
acting ephrins are defined by the sum of cell surface–expressed 
receptors of the corresponding subtype (Pasquale, 2010). A re-
cent study suggests that in prostate carcinoma cells, coexpressed 
EphA and -B receptors generate disparate responses to ephrin 
contact, whereby EphB signaling promotes unhindered migra-
tion, whereas EphA signaling mediates contact-inhibited mi-
gration toward ephrin-expressing cells (Astin et al., 2010). In 
view of the Eph/ephrin subclass specificity, it was proposed that 
preferential activation of either EphA or EphB receptors and 
their signaling from distinct EphA and EphB clusters will dictate 
the response of these cells to interacting ephrin-expressing cells. 
We have now explored the possibility that A- and B-type Ephs 
directly associate and participate in a common signaling cluster 
that elicits cellular responses according to its composition from 
both receptors.
Previously,  functional  analysis  of  Eph/ephrin  signal 
cluster assembly revealed that propagation of nascent signaling 
clusters could occur independent of ephrin contacts and cyto-
solic Eph signaling functions via direct Eph–Eph interactions 
(Lackmann et al., 1998; Wimmer-Kleikamp et al., 2004). Re-
cent crystal structures defined the involved molecular interfaces 
within the globular and cysteine-rich Eph receptor domains 
(Himanen et al., 2010; Seiradake et al., 2010), but these stud-
ies did not explore whether the same mechanism may also 
heterooligomerize EphA and EphB receptors. We now confirm 
in prostate carcinoma and in glioma cell lines with endogenous 
EphA and EphB coexpression and in EphA3/EphB2 coex-
pressing HEK293 and COS7 cells used as in vitro models that 
constitutive association of two receptor subtypes is increased   
upon selective clustering of only one of the two receptors. We 
used confocal microscopy and FLIM to assess the association 
of EphA and EphB receptors and the proximity of their inter-
action  in  intact  cells.  In  FLIM,  FRET  attenuation  of  donor 
fluorescent lifetimes depends on the proximity of interacting 
fluorophores within 10 nm (Wouters et al., 2001; Jares-Erijman 
and Jovin, 2003), and substantially reduced donor fluorescent 
lifetimes determined in our experiments indeed suggest very 
close and potentially direct interactions between the GFP and 
diHcRed-tagged Eph receptors. This notion is supported by our 
functional analysis, strongly suggesting that the Eph receptor 
kinase domains are in sufficient close juxtaposition to allow 
Figure  7.  Overexpression  of  kinase-inactive  EphA3  causes  dominant- 
negative inhibition of ephrin-B1/EphB2–mediated cell segregation. (A) GFP-
EphB2/HEK293 cells, transfected with Wt or EphA3[KM], were stained 
with Alexa Fluor 594 -EphA3 mAb and enriched by FACS. Transfected 
or  control  GFP-EphB2/HEK293T  cells  were  cocultured  with  ephrin-B1/
HEK293T cells until confluent before imaging by fluorescence microscopy. 
All scale bars are in micrometers. (B) Segregation of GFP-EphB2/HEK293T 
and ephrin-B1/HEK293T cells was quantified as in Fig. 6 (10 random 
fields/condition). The graph shows means with error bars indicating 95% 
confidence intervals (ANOVA test for multiple comparisons).JCB • VOLUME 195 • NUMBER 6 • 2011   1042
development; increasing coexpression of cytoplasmic-truncated 
splice variants changes the response to ephrin-A5–expressing 
cells from repulsion to adhesion to facilitate effective closure 
of the neural tube (Holmberg et al., 2000). Whereas in this case 
a  dose-dependent  dominant-negative  effect  was  shown  to   
inhibit activation and reverse Wt EphA7 function, in other 
examples, the underlying signaling mechanisms are less well 
defined,  and  kinase-independent  Eph  functions  have  been 
postulated. For example, analysis of EphA8-triggered adhe-
sion via 1 or 3 integrins in transfected NIH3T3 or HEK293 
cells suggested a phosphatidylinositol 3-kinase (PI3K)-depen-
dent mechanism that is independent of EphA8 kinase activity 
but is reliant on the presence of the EphA8 extracellular and 
juxtamembrane domains (Gu and Park, 2001). Likewise, a role 
of kinase-defective EphB6 in cell adhesion and migration was 
examined by transfection of HEK293T cells, revealing enhan-
ced adhesion and migration at low, but repulsion and attenu-
ated cell migration at high, ephrin-B2 concentrations (Matsuoka 
et al., 2005), whereas tyrosine phosphorylation and loss of cell 
adhesion in HEK293T cells overexpressing ephrin binding–
compromised  EphB4  were  considered  to  reflect  ephrin- 
independent EphB4 tumor cell functions (Noren et al., 2009). 
Also, in PC3 cells, transfection with mutant EphA2 revealed 
EphA2 kinase-independent effects on cell migration and inva-
sion (Taddei et al., 2009). Considering our finding of coassoci-
ation and crosstalk between different Ephs, it would seem 
possible that endogenous expression of other Eph receptors, 
including EphA3 in HEK293 cells (Dottori et al., 1999) and 
EphB2 in PC3 cells (Astin et al., 2010), may have contributed 
to the signaling outcomes in these cells.
Given the high frequency of somatic cancer mutations 
in the genes of Eph receptors, in particular EphA3, which are 
likely to effect receptor clustering or kinase activity (Sjöblom 
et al., 2006; Ding et al., 2008), the contrary contributions of 
either low- or high-expressed kinase-defective Eph receptors 
to  Eph-controlled  cell–cell  adhesion  will  undeniable  have 
important functional relevance. Of note, the molecular switch 
between adhesive and de-adhesive responses to Eph-ephrin   
ligation is provided by distinct configurations of the active or 
inactive Eph kinase domain–controlling ADAM10-mediated 
ephrin cleavage and Eph endocytosis (Janes et al., 2009).   
A kinase-dead nonphosphorylated Eph remains bound to cell 
surface ephrins, is not endocytosed (Janes et al., 2009; Niever-
gall et al., 2010), and promotes stable cell–cell contacts. Thus, 
occurrence  of  Eph  kinase–inactivating  mutations  cannot  be 
considered as a loss of function analogous to a loss of protein 
expression but as a mechanism that switches the response to 
neighboring ephrin-expressing cells from cell–cell segregation 
to cell–cell adhesion and intermingling (Lackmann and Boyd, 
2008). Our finding of crosstalk between Eph family members 
potentially relaying this reversal of response to ephrin contact 
across the combined Eph population on a cell has considerable 
implications for the understanding of Eph functions in cancer. 
It suggests that one may need to consider overall Eph fam-
ily expression profiles rather than individual family members 
when examining the biological responses that are controlled by 
these cell guidance receptors.
potential contribution also of the N-terminal fibronectin type 
III (FNIII) motif to the Eph–Eph interface, although functional 
evidence for this interaction is lacking. Indeed, almost complete 
loss of heteroclustering between EphB2 and EphA2/3 LBD 
mutants in our experiments would seem to confirm the dominat-
ing role proposed for these particular domains to the clustering 
interface (Himanen et al., 2010).
Interestingly, selective biotinylation and subsequent clus-
tering and activation with SA beads of biotinylated AP-EphB2 
also trigger activation/phosphorylation, as was initially shown 
for EphA3 (Howarth and Ting, 2008; Nievergall et al., 2010), in 
which localized clustering of biotinylated EphA3 onto SA beads 
allowed detecting the recruitment of the ER-bound phosphatase 
PTP1B into cell surface EphA3 signaling clusters (Nievergall 
et al., 2010). In our current study, the same approach unam-
biguously revealed that EphB2 is recruited, independent of   
interaction with ephrins, into the EphA3 cell surface cluster.   
A recent study suggests that to further the contribution of Eph–
Eph  clustering  mechanisms  previously  described  (Wimmer-
Kleikamp et al., 2004) and in the current study, Eph-modulated 
actomyosin contractile forces may potentially participate in as-
sembly and lateral expansion of Eph clusters, providing a posi-
tive feedback loop during Eph activation (Salaita et al., 2010). The 
involvement of such a mechanism would explain why in our 
experiments cytoplasmic truncation of EphA3 also weakly 
attenuates the association with EphB2.
Conceptually, it may seem to make little difference to 
the biological response if functionally distinct EphA and EphB 
receptors contribute from separate or shared signaling clusters, 
considering that some of the downstream signaling components 
will be shared (Pasquale, 2005), and, invariably, the abundance of 
one receptor type will dictate the overall response to ephrin 
contact.  However,  previous  models  considered  that  distinct 
EphA and EphB signaling clusters are only activated if eph-
rins binding to corresponding subclasses are present on the 
interacting  cells  (Lemke  and  Reber,  2005;  Lackmann  and 
Boyd, 2008; Pasquale, 2010). Our findings now suggest that 
even in the absence of ephrins with specificity for one of the 
Eph subtypes, the recruitment and functional association of 
EphA and EphB receptors within the common complex lead to 
signaling outcomes that reflect composite Eph clusters, poten-
tially containing both Eph subclasses. Importantly, depending 
on the ratio between Wt and mutant Eph family members 
expressed in a cell, kinase-inactivating mutations of one Eph 
are either rescued by transphosphorylation or exert a dominant- 
negative  effect  on  the  Wt  receptor.  Thus,  coexpression  of 
moderate levels of kinase-defective EphA3 in COS7 cells with   
endogenous EphB2 expression results in its transphosphoryla-
tion by EphB2 and renders these cells responsive to cell con-
traction by the agonistic IIIA4 antibody. On the other hand, 
highly  elevated  expression  of  the  kinase-defective  EphA3 
modulates signaling from the Eph cluster in a dominant- 
negative manner by strongly attenuating EphB2 phosphoryla-
tion, cell rounding, and segregation from ephrin-B1 cells.
A prominent example for a kinase-defective Eph receptor 
modulating signaling outcomes of its Wt parent is EphA7, 
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visualized  using  HRP-coupled  secondary  antibodies  (Jackson  Immuno-
Research Laboratories, Inc.) and an ECL substrate (SuperSignal; Thermo 
Fisher Scientific).
Quantitative PCR analysis of glioma tissue
Primary specimens were obtained from the Royal Brisbane and Women’s 
Hospital and the Briz Brain and Spine Research Foundation after informed 
consent from adult patients diagnosed with high-grade glioma. RNA was 
extracted using TRIZOL (Invitrogen). First-strand cDNA was synthesized 
using random hexamers and Superscript III (Invitrogen). Real-time PCR 
was performed using SYBR green PCR Master Mix (Applied Biosystems). 
Cycling conditions were 15 min at 95°C and 30 cycles of 30 s at 95°C, 
30 s at 55°C, and 30 s at 72°C.
Confocal and fluorescence microscopy analysis
Confocal microscopy was performed with a microscope (FluoView 1000; 
Olympus) equipped with 488-nm argon, 543-nm helium–neon, and 633-
nm helium–neon lasers using an oil immersion 60× objective lens (1.4 
NA). Cells were plated into fibronectin-treated coverslips, transfected, and 
stained as indicated. Images were analyzed with analySIS software (Soft 
Imaging System), and merging of micrographs from individual fluorescent 
channels (Figs. 2 and S3) was performed in Photoshop (Adobe).
FLIM sequences were obtained at a modulation frequency of 80 
MHz with a microscope (IX70; Olympus) using a 100×/1.4 NA oil objec-
tive. EYFP was excited with the 514-nm line of an argon ion laser. The ac-
ceptor fluorophore diHcRed was imaged using a 100-W mercury arc lamp 
and a Texas red filter set. FLIM data were processed using IPLab software 
(Scanalytics)  and  a  custom-designed  script,  as  previously  described 
(Verveer et al., 2000). Fluorescence lifetime images are presented in 
pseudocolor. Images show YFP fluorescence phase-modulation lifetimes. 
Imaging of cells for retraction and segregation assays was performed on 
an imaging system (AF6000 LX; Leica) equipped with N Plan 20× (0.35 
NA) and FLUOstar 40× (0.6 NA) dry objectives using time-lapse and multi-
point positioning functions.
Cell retraction and segregation assays
Eph-mediated cell retraction was assayed using COS7 cells plated into   
8-well chamber slides (BD) precoated with 10 µg/ml fibronectin. Cells 
were prestained on ice with 5 µg/ml Alexa Fluor 594–labeled anti-EphA3 
(IIIA4) antibody, washed once, and imaged by time lapse after an addition 
of 0.75 µg/ml anti–mouse IgG to cross-link the antibody-bound receptors.
Cell segregation assays were performed essentially as previously 
described (Poliakov et al., 2008). In brief, a total of 60,000 cells/well 
containing labeled and nonlabeled Eph and ephrin-expressing cells, as in-
dicated, was seeded into fibronectin-precoated 8-well chamber slides (BD) 
and incubated for 2 d or until confluent. Where indicated, one cell popula-
tion was prelabeled with CellTracker green (Invitrogen), as per the manu-
facturer’s instructions. Images were taken at identical settings and analyzed 
with ImageJ software (National Institutes of Health) to determine fluores-
cence intensity (green channel) divided by the area of fluorescence as a 
measure of tightness of segregation of the two cell populations. Merging of 
fluorescent and brightfield micrographs was performed in Photoshop.
Online supplemental material
Fig. S1 shows expression of individual receptors or combined subsets of 
EphA and EphB receptors in glioma patient tumor tissue samples. Fig. S2 
shows analysis by IP/WB of EphA and EphB receptor coassociation and 
cross-phosphorylation in tumor cell lines. Fig. S3 illustrates the association 
between EphA3 and EphB2 by confocal microscopy, IP, and FRET analy-
sis. Fig. S4 shows IP/WB analysis revealing that EphA3 is not activated by 
ephrin-B1-Fc but is slightly activated by coincubation with HEK293 cells. 
Video 1 shows a time lapse of Alexa Fluor 594 IIIA4–induced contraction 
of a Wt EphA3–transfected COS7 cell. Video 2 illustrates Alexa Fluor 594 
IIIA4–induced contraction of an EphA3[KM]-transfected COS7 cell. Video 3   
shows that time-lapse microscopy of a group of Wt EphA3–expressing 
COS7 cells reveals ephrin-B1–induced cell contraction. Video 4 shows 
ephrin-B1–induced cell contraction of a Wt EphA3–expressing COS7 cell. 
Video 5 illustrates time-lapse microscopy of COS7 cells overexpressing 
signaling-defective  EphA3[KM],  which  do  not  respond  to  ephrin-B1-Fc 
exposure with contraction. Video 6 reveals limited ephrin-B1-Fc–induced 
contraction of a single COS7 cell with low EphA3[KM] expression among 
a group of EphA3[KM]-overexpressing COS7 cells.
We  thank  Juha  Himanen  and  Dimitar  Nikolov  for  providing  ephrin-B1-Fc,   
Andrew Scott, Angelo Peroni, and Benjamin Gloria for IIIA4 antibody production, 
and David Wilkinson and Alexi Poliakov for providing 293/ephrin-B1 and 
Materials and methods
Expression constructs
A  parental  pEFBos  EphA3  expression  plasmid  comprising  the  cDNA- 
encoding residues 1–983 of human EphA3 cloned into the pEF-BOS vec-
tor under control of the human EF-1 promoter (Lackmann et al., 1998) 
was used for construction of EphA3-GFP (Wimmer-Kleikamp et al., 2004), 
EphA3-YFP (Nievergall et al., 2010), and EphA3-diHcRed (Janes et al., 
2005). EphA3 tagged with a biotin AP or Avi-tag (EphA3-AP; Janes   
et al., 2009) was used for making deletion mutants lacking the LBD (lack-
ing residues 44–211) or CRD (residues 212–335) by insertion of BstZ17I 
restriction sites using site-directed mutagenesis (Agilent Technologies) and 
religation. Intracellular deletion was performed by insertion of a stop 
codon  at  Tyr570.  GFP-tagged  EphA2  extracellular  domain,  generated 
by cloning full-length human EphA2 from a Mammalian Gene Collection 
cDNA template into pEGFP-N2 (Invitrogen), was used to generate EphA2 
extracellular  domain  deletion  mutants  lacking  residues  28–198  (LBD) 
or replacing residues 201–325 (CRD) with a Gly-Ser-Gly-Ser linker by 
PCR-based cloning strategies, as previously described (Himanen et al., 
2010). Mouse EphB2-GFP was generated within the mammalian expres-
sion vector pcDNA3 by inserting the GFP cDNA in between C-terminal 
residues Arg983 and Ala984 of EphB2, as previously described (Tong 
et al., 2003). From this vector, we generated EphB2 3YF using site- 
directed mutagenesis to alter Tyr604, -610, and -667 into Phe. EphB2-AP 
was made by insertional site-directed mutagenesis of the AP tag sequence 
after Val19 of the mouse EphB2 signal sequence, as previously described 
for EphA3 (Janes et al., 2009).
Reagents and antibodies
Ephrin-A5-Fc was produced in a CHO cell clone containing a mammalian 
pIgBos cDNA expression plasmid in which the full-length ephrin-A5 (resi-
dues 1–228) in pBluescript is fused to the hinge and CH2 and CH3 re-
gions of human IgG1; the ephrin-A5-Fc fusion protein was purified from the 
cell supernatants by successive protein A affinity chromatography and size-
exclusion HPLC. Ephrin-B1-Fc, generated by a similar strategy, was pro-
vided by J. Himanen (Memorial Sloan-Kettering Cancer Center, New York, 
NY) and has been previously described (Lawrenson et al., 2002). Proper-
ties  of  the  activating  EphA3-specific  mAb  (clone  IIIA4;  Vearing  et  al., 
2005) and the EphA3 sheep pAb used for immunoblots (Nievergall et al., 
2010) have been previously described. Commercially available antibodies 
were used for EphB2 (pAb; R&D Systems), phospho-EphA3 (pAb; Millipore), 
PY (pAb; Invitrogen), GFP (mAb; Roche), and the AP tag (Avi-tag pAb; Gen-
Script). SA M-280 Dynabeads and protein A Dynabeads were obtained 
from Invitrogen. Alexa Fluor–labeled SA and secondary antibodies were 
obtained from Molecular Probes, as were kits for Alexa Fluor labeling of 
IIIA4 mAb. Immunoprecipitation of antibody-bound proteins was with 
protein  A  Sepharose  (CL4B;  GE  Healthcare),  except  for  EphA3,  for 
which IIIA4-coupled Mini-Leak beads (Vearing et al., 2005) were used 
(Kem-En-Tec Diagnostics).
Cell culture and biochemical analysis
HEK293, COS7, and U251 glioma and PC3, DU145, and LNCaP pros-
tate cancer cell lines were obtained from the American Type Culture Col-
lection and maintained in DME, 10% FCS, and 2 mM  l-Glutamine in 
5% CO2. Stably transfected HEK293 cells expressing ephrin-B1 or coex-
pressing EphB2 with membrane-targeted GFP (gapGFP) were provided by   
D. Wilkinson and A. Poliakov (Medical Research Council National Insti-
tute for Medical Research, London, England, UK; Poliakov et al., 2008) 
and were maintained in the presence of 200 µg/ml G418. EphB2 lacking 
the cytoplasmic domain (EphB2ICD) was generated by stably transfect-
ing HEK293 cells with a mammalian expression construct for cytoplasmic- 
truncated EphB2 (Poliakov et al., 2008), using G418 for selection. Ex-
pression levels in these cells were tested by immunoblotting of cell lysates, 
immunofluorescence,  and  FACS,  as  previously  described  (Jørgensen   
et al., 2009). HEK293 and COS7 cells stably expressing EphA3 Wt or 
inactive mutant EphA3[KM] were generated by antibiotic selection with 
200 µg/ml Zeocin (Invitrogen).
Stimulation of cells was performed with ephrin-A5-Fc or ephrin-B1-
Fc (1.5 µg/ml final) preclustered using anti–human IgG (0.75 µg/ml Fc- 
specific; Jackson ImmunoResearch Laboratories, Inc.) or IIIA4 (1.5 µg/ml 
final) preclustered using anti–mouse IgG, typically for 15 min. Whole-cell 
lysis was performed in 50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton 
X-100, 0.1% SDS, 1 mM NaV04, 10 mM NaF, and protease inhibitors 
(Complete; Roche). IPs or whole-cell lysates were analyzed by SDS-PAGE 
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